Clinical Pancreatology for Practising Gastroenterologists and Surgeons. Группа авторов

Clinical Pancreatology for Practising Gastroenterologists and Surgeons - Группа авторов


Скачать книгу
systemic inflammation, and vascular shunting. This highlights the need for a more sensitive and specific biomarker that can detect intravascular volume deficit at the earliest stage. While novel noninvasive tools have been developed to dynamically measure volume deficit in other clinical settings, none have been extrapolated for use in AP patients [39,40].

      Fluid sequestration and intra‐abdominal hypertension are other important phenomena relative to AP severity. Patients often have systemic capillary leak syndrome leading to severe “third‐spacing” of fluids. Age under 40 years, alcohol etiology, hemoconcentration, and presence of SIRS are risk factors for fluid sequestration and predicted severity of AP [41,42]. Aggressive fluid resuscitation in this population will eventually lead to intra‐abdominal hypertension and compartment syndrome, which portends a poor prognosis [43]. As such, intra‐abdominal pressure as measured via a urinary catheter has been examined as a predictor of severity with promising results [44]. At a biomarker level, angiopoietin‐2, a regulator of capillary permeability, has been shown to predict severe pancreatitis [45,46].

      Inflammatory Response

      Starting with acinar cell injury by a variety of pancreatic toxins, systemic inflammation occurs as early as the first few hours of the inciting parenchymal injury [15]. SIRS is a clinically evident syndrome that is a manifestation of the host’s exaggerated immune response to a local organ injury. SIRS secondary to sterile pancreatic inflammation is the predominant event in the first two weeks and its severity and progression to organ failure determines the fate of patients [2]. SIRS has long been recognized as a harbinger of disease severity. Several studies have shown that SIRS, especially when persistent for 48 hours or longer, is associated with increased risk of mortality [23].

      Host‐related Characteristics

      Age and Comorbidity Burden

      Increased age and comorbid conditions do not mediate increased pancreatitis severity, but rather reduce a patient’s reserve to survive an extreme physiological stress [19]. Patients older than 75 years of age are at significantly increased risk of mortality at one and three months when compared with patients 35 years of age and younger. Similarly, a high Charlson Comorbidity Index is associated with increased mortality. While comorbidity burden is not typically included in a scoring system, age is part of most scoring systems (see Table 4.1).

      Obesity and Hypertriglyceridemia

Name of cytokine, chemokine or adipokine Function AUC for severe pancreatitis or mortality
Interleukin‐1β Proinflammatory cytokine: stimulates macrophages, causes lymphocyte maturation; induces acute‐phase protein production; facilitates leukocyte trafficking 74–82% [55]
Interleukin‐6 Proinflammatory cytokine: regulates T lymphocytes activation and differentiation, causes lymphocyte maturation; induces acute‐phase protein production; facilitates neutrophil trafficking to the site of injury; strongly associated with acute lung injury in acute pancreatitis 75–88% [55–57]
Interleukin‐8 Proinflammatory cytokine 73–76% [55,57]
TNF‐α Proinflammatory cytokine: induces acute‐phase protein production; activates neutrophils and macrophages 81% [58]
Angiopoietin‐2 Autocrine peptide regulator of vascular permeability 74–81% [46,59]
Resistin Adipokine: induces production of IL‐1β, IL‐6 and TNF‐α 76–80% [60,61]
Visfatin Adipokine: induces production of IL‐1β, IL‐6 and TNF‐α 74% [62,63]
Monocyte chemotactic protein‐1 Chemokine secreted early in the disease course to recruit monocytes, lymphocytes, mast cells, and eosinophils 88% [64]

      Degree of Parenchymal and Extra‐parenchymal Injury


Скачать книгу